News

Under the terms of the agreement, Tacere and Pfizer will form a joint steering committee to oversee preclinical R&D efforts for TT-033. Pfizer will fund all aspects of

Safety needles are products used to access patients’ blood during the vast majority of chronic dialysis therapy treatments. MasterGuard is claimed to be the leading product in this

Orphan drug designation would entitle Fovea to exclusive marketing rights in the European countries for 10 years should Fovea be the first company to receive marketing approval for

According to MedSpas of America, its all-natural products contain a uniquely exotic and effective combination of hibiscus flower and kukui nut oil. The company will immediately re-brand this

The business will be renamed Cambrex Tallinn after completion of the acquisition. Cambrex intends to add more process and analytical chemists at the site and continue early active

Baxter will develop both an unmodified recombinant Factor IX therapy for treatment of acute bleeding episodes and a chemically modified, long-acting version of recombinant Factor IX therapy for

The study has met its primary endpoint of a statistically significant reduction in incontinence episodes, and secondary endpoints of reduction in frequency and increases in void volume compared

As part of the strategic relationship, Genzyme will also have preferred access to future Isis drugs for central nervous system and certain rare diseases. Genzyme will pay Isis

This Phase Ib study was designed to assess the safety, tolerability and pharmacokinetics of once-daily, orally administered doses of either 2.5gm or 5gm of SRT501 in patients with